Novo Nordisk Stock Slips
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.
Novo CEO, Sanders to Face Off Over US Prices for Ozempic and Wegovy
In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard Jørgensen will be asked to defend the drugs’ U.S. monthly list prices of $969 and $1,
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions.
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Novo Nordisk faces US Senate committee grilling over price of weight loss drugs
was $468 now $279 for your first year. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Offer available here until 24th October.
Senate HELP Committee hearing could get heated as Novo Nordisk CEO testifies
Novo Nordisk CEO faces Senate showdown over high prices for diabetes and weight loss drugs Ozempic and Wegovy.
Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics
Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a ...
Novo CEO to blame drug middlemen
The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...
Novo CEO Faces Sanders Over GLP-1 Drug Prices. All of Pharma Should Tune In.
A Senate hearing Tuesday will look at why the list prices of Ozempic and Wegovy are much higher in the U.S. than in ...
Ozempic and Wegovy Sales Will Soon Pay for $68 Billion of Novo R&D
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Preço do Ozempic fica mais difícil para Novo Nordisk justificar
O faturamento da farmacêutica dinamarquesa Novo Nordisk com o Ozempic e o Wegovy é tanto que as vendas acumuladas logo ...